PK of Uprifosbuvir and Ruzasvir in Hepatic Insufficiency

Phase 1, open-label trial of uprifosbuvir and ruzasvir in hepatitis C (HCV) (3 arms), sponsored by Merck & Co. Primary endpoints: Area Under the Drug Plasma Concentration-Time Curve From Start of Dosing to Time of the Last Quantifiable Sample, Area Under the Drug Plasma Concentration-Time Curve From Start of Dosing to Infinity and 8 more. Started Jan 2016; status: completed.